Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 04/09/2007
Entire Document
 
 

  (ii)   conceived jointly by one or more AGENTS of CYPRESS and one or more AGENTS of OREXIGEN in the course of the COLLABORATIVE WORK.
  1.13   COLLABORATIVE WORK” shall have the meaning given in Section 4.01.
 
  1.14   COLLABORATIVE WORK PLAN” shall have the meaning given in Section 4.01.
 
  1.15   CYPRESS INDEMNITEES” shall have the meaning given in Section 14.02.
 
  1.16   CYPRESS MATERIALS” means any proprietary materials provided by CYPRESS to OREXIGEN as part of the COLLABORATIVE WORK.
 
  1.17   DISPUTE” shall have the meaning given in Section 20.02.
 
  1.18   DUKE AGREEMENT” means that certain License Agreement dated March 31, 2004, by and between Duke University and OREXIGEN, as amended by Amendment No. 1 thereto, dated as of even date herewith.
 
  1.19   DUKE PATENT RIGHTS” means the patents and patent applications listed on APPENDIX A, together with all divisions, continuations, continuations-in-part (but only to the extent that the subject matter of each such continuation-in-part application is described in and enabled by the disclosure of such patent applications listed on APPENDIX A), re-examinations, reissues, substitutions, or extensions thereof and patents issuing therefrom in the United States and non-U.S. jurisdictions, which are licensed to OREXIGEN under the DUKE AGREEMENT.
 
  1.20   DUKE SUBLICENSE” means the sublicense under the DUKE AGREEMENT to practice under the DUKE PATENT RIGHTS, which is included in the LICENSE.
 
  1.21   ELAN PARTIES” shall have the meaning given in Section 14.02.
 
  1.22   FIELD” means all human indications.
 
  1.23   FINAL DECISION” shall have the meaning given in Section 20.04(c).
 
  1.24   IMPROVEMENT” means any invention that is an improvement to, or modification, of an existing invention claimed in any patent application or patent within the INTELLECTUAL PROPERTY of a party.
 
  1.25   INTELLECTUAL PROPERTY” means all intellectual property rights worldwide arising under statutory or common law, and whether or not perfected, including, without limitation, all (A) patents and patent applications now existing or hereafter filed, issued or acquired, together with all divisions, continuations, continuations-in-part (but only to the extent that the subject matter of each such

- 3 -